GENFIT acquires Swiss biotech Versantis for up to CHF105 million

GENFIT, a late-stage biopharmaceutical company focussed on severe chronic liver diseases, has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases.
Read the full article on Startupticker